{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:33:05Z","timestamp":1790742785253,"version":"4.1.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Editor\u2019s Perspective<\/jats:title>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>What We Already Know about This Topic<\/jats:title>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>What This Article Tells Us That Is New<\/jats:title>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Tachycardia is a hallmark of sepsis. An elevated heart rate could impair ventricular filling and increase myocardial oxygen demand. \u03b2-Blockers and ivabradine (a selective inhibitor of I<jats:italic toggle=\"yes\">f<\/jats:italic> channels in the sinoatrial node) are both able to control sinus tachycardia, with the latter drug being devoid of negative inotropic effect. This work aimed at assessing the hemodynamic effects of ivabradine as compared with a \u03b2-blocker (atenolol) during murine peritonitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Ivabradine (3 \u03bcg\/g), atenolol (3 \u03bcg\/g), or placebo was administered intraperitoneally 2 h after induction of peritonitis (cecal ligation and puncture) in male C57BL6 mice. The authors used invasive (left ventricular catheterization) and noninvasive (transthoracic echocardiography) monitoring to assess hemodynamics 20 h after surgery, including heart rate, blood pressure, left ventricular systolic, and diastolic function (n = 10 mice\/group). The authors also assessed overall mortality 30 and 60 h after surgery in a distinct subset of animals (n = 20 mice\/group). Descriptive data are presented as median (25th to 75th percentile).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>As compared with placebo (601 beats\/min [547 to 612]), ivabradine (447 beats\/min [430 to 496]) and atenolol (482 beats\/min [412 to 505]) blunted sepsis-induced tachycardia assessed by transthoracic echocardiography in awake animals (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001 and <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.004, respectively). Unlike ivabradine, atenolol reduced cardiac output, systolic blood pressure, and left ventricular systolic function (as assessed by ejection fraction, maximal left ventricular pressure rise, and anterior wall strain rate) as compared with septic mice receiving placebo. There was no difference in survival 60 h after sepsis induction with ivabradine (6 of 20, 30%) or atenolol (7 of 20, 35%), as compared with placebo (5 of 20, 25%; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.224).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Heart rate control could be similarly achieved by ivabradine or atenolol, with preservation of blood pressure, cardiac output, and left ventricular systolic function with the former drug.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aln.0000000000003045","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T06:35:33Z","timestamp":1574663733000},"page":"321-329","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":28,"title":["Heart Rate Control during Experimental Sepsis in Mice"],"prefix":"10.1097","volume":"132","author":[{"given":"Alexandre","family":"Bedet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Voiriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Ternacle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Adnot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Derumeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Mekontso Dessap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20241219","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJMoa022139","article-title":"The epidemiology of sepsis in the United States from 1979 through 2000.","volume":"348","year":"2003","journal-title":"N Engl J Med"},{"key":"R2-20241219","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1164\/rccm.2201087","article-title":"Current epidemiology of septic shock: The CUB\u2013R\u00e9a Network.","volume":"168","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"R3-20241219","first-page":"2693","article-title":"Score-based immunoglobulin G therapy of patients with sepsis: The SBITS study.","volume":"35","year":"2007","journal-title":"Crit Care Med"},{"key":"R4-20241219","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","article-title":"Drotrecogin alfa (activated) in adults with septic shock.","volume":"366","year":"2012","journal-title":"N Engl J Med"},{"key":"R5-20241219","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/00003246-198710000-00006","article-title":"Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: Heart rate as an early predictor of prognosis.","volume":"15","year":"1987","journal-title":"Crit Care Med"},{"key":"R6-20241219","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/qjmed\/hcm074","article-title":"Relative tachycardia in patients with sepsis: An independent risk factor for mortality.","volume":"100","year":"2007","journal-title":"QJM"},{"key":"R7-20241219","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00392-011-0375-3","article-title":"Heart rate as an independent risk factor in patients with multiple organ dysfunction: A prospective, observational study.","volume":"101","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"R8-20241219","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jama.2013.278477","article-title":"Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: A randomized clinical trial.","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"R9-20241219","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1007\/s00134-016-4351-2","article-title":"Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: A prospective observational study.","volume":"42","year":"2016","journal-title":"Intensive Care Med"},{"key":"R10-20241219","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1007\/s00134-011-2236-y","article-title":"Effects of esmolol on systemic and pulmonary hemodynamics and on oxygenation in pigs with hypodynamic endotoxin shock.","volume":"37","year":"2011","journal-title":"Intensive Care Med"},{"key":"R11-20241219","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.","volume":"43","year":"2017","journal-title":"Intensive Care Med"},{"key":"R12-20241219","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000073933","article-title":"A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction.","volume":"100","year":"2003","journal-title":"Cardiology"},{"key":"R13-20241219","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijcard.2016.09.054","article-title":"Effect of ivabradine on central aortic blood pressure in patients with stable coronary artery disease: What do we know?","volume":"224","year":"2016","journal-title":"Int J Cardiol"},{"key":"R14-20241219","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.cardfail.2009.05.013","article-title":"Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: Preliminary findings.","volume":"15","year":"2009","journal-title":"J Card Fail"},{"key":"R15-20241219","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1136\/heartjnl-2012-302795","article-title":"Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients.","volume":"98","year":"2012","journal-title":"Heart"},{"key":"R16-20241219","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/ALN.0000000000001431","article-title":"Ivabradine attenuates the microcirculatory derangements evoked by experimental sepsis.","volume":"126","year":"2017","journal-title":"Anesthesiology"},{"key":"R17-20241219","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial.","volume":"372","year":"2008","journal-title":"Lancet"},{"key":"R18-20241219","first-page":"2860","article-title":"Cecal ligation puncture procedure.","year":"2011","journal-title":"J Vis Exp"},{"key":"R19-20241219","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1161\/01.CIR.0000129774.09737.5B","article-title":"HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis.","volume":"109","year":"2004","journal-title":"Circulation"},{"key":"R20-20241219","first-page":"697","article-title":"Direct relationship between in vitro If current inhibition by ivabradine and heart rate in the mouse.","volume":"31","journal-title":"Eur Heart J."},{"key":"R21-20241219","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.phrs.2006.03.016","article-title":"The discovery of the selective I(f) current inhibitor ivabradine: A new therapeutic approach to ischemic heart disease.","volume":"53","year":"2006","journal-title":"Pharmacol Res"},{"key":"R22-20241219","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/nprot.2008.138","article-title":"Measurement of cardiac function using pressure\u2013volume conductance catheter technique in mice and rats.","volume":"3","year":"2008","journal-title":"Nat Protoc"},{"key":"R23-20241219","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1164\/ajrccm.160.2.9810073","article-title":"Inappropriate sympathetic activation at onset of septic shock: A spectral analysis approach.","volume":"160","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"R24-20241219","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/CCM.0b013e3181c03dfa","article-title":"Cardioprotection, attenuated systemic inflammation, and survival benefit of \u03b21-adrenoceptor blockade in severe sepsis in rats.","volume":"38","year":"2010","journal-title":"Crit Care Med"},{"key":"R25-20241219","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1097\/01.CCM.0000182796.11329.3B","article-title":"Infusion of the \u03b2-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats.","volume":"33","year":"2005","journal-title":"Crit Care Med"},{"key":"R26-20241219","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00134-017-4698-z","article-title":"Left ventricular systolic dysfunction during septic shock: The role of loading conditions.","volume":"43","year":"2017","journal-title":"Intensive Care Med"},{"key":"R27-20241219","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study.","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"R28-20241219","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1161\/CIRCULATIONAHA.112.000145","article-title":"New therapeutic targets in cardiology: Heart failure and arrhythmia: HCN channels.","volume":"127","year":"2013","journal-title":"Circulation"},{"key":"R29-20241219","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/SHK.0000000000000593","article-title":"If channel inhibition with ivabradine does not improve cardiac and vascular function in experimental septic shock.","volume":"46","year":"2016","journal-title":"Shock"},{"key":"R30-20241219","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s00134-015-3748-7","article-title":"Diastolic dysfunction and mortality in septic patients: A systematic review and meta-analysis.","volume":"41","year":"2015","journal-title":"Intensive Care Med"},{"key":"R31-20241219","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1097\/01.CCM.0000266683.64081.02","article-title":"Mechanisms of sepsis-induced cardiac dysfunction.","volume":"35","year":"2007","journal-title":"Crit Care Med"},{"key":"R32-20241219","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/cc8026","article-title":"Bench-to-bedside review: \u03b2-Adrenergic modulation in sepsis.","volume":"13","year":"2009","journal-title":"Crit Care Lond Engl"},{"key":"R33-20241219","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/0267659108094528","article-title":"Direct effects of volatile anesthetics on cardiac function.","volume":"23","year":"2008","journal-title":"Perfusion"}],"container-title":["Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/pubs.asahq.org\/anesthesiology\/article-pdf\/132\/2\/321\/516396\/20200200_0-00018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/anesthesiology.pubs.asahq.org\/article.aspx?doi=10.1097\/ALN.0000000000003045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T13:57:47Z","timestamp":1735912667000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ALN.0000000000003045"}},"subtitle":["Comparison of Ivabradine and \u03b2-Blockers"],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/aln.0000000000003045","relation":{},"ISSN":["0003-3022"],"issn-type":[{"value":"0003-3022","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}